Studies in ‘in vivo’ models, genome wide screening, identification of novel subsets of AR-positive immune cells, design and synthesis of new AR inhibitors/modulators with strong efficacy and tissue selectivity might provide new hints in this direction to achieve a better therapeutic efficacy in melanoma patients. Here, AR is linked to melanoma.